Skip to content
Medical Health Aged Care, Research Development

Study identifies new treatment targets for vascular dementia

Centre for Healthy Brain Ageing (CHeBA), UNSW Sydney 3 mins read
Key Facts:

• Vascular dementia is common, serious, and currently has no approved treatments
• It is caused by damage to blood vessels in the brain
• New research has identified potential biological targets to guide future studies
• Translating these findings into treatments will require substantial further research
• Genetics-led approaches may help uncover new pathways for future therapies


A new study led by researchers at UNSW Sydney’s Centre for Healthy Brain Ageing (CHeBA) has identified potential biological targets that could help guide future research into treatments for vascular dementia – a common and serious yet currently untreatable form of dementia.

Vascular dementia, caused by damage to blood vessels in the brain, is the second most common form of dementia worldwide, accounting for around 15–20% of all cases. Despite its prevalence and impact, there are currently no approved treatments in Australia for this condition.

Dr Matthew Lennon, lead author of the study published in Alzheimer's & Dementia: Translational Research & Clinical Interventions, a journal of the Alzheimer’s Association, says the findings represent an early but important step in a longer research journey.

“Vascular dementia is a major and growing public health problem. It affects memory, thinking, and function, yet we have no effective treatments to stop or slow its progression. Our study provides an initial step by identifying biologically plausible targets that could inform future research into therapies,” said Dr Lennon.

Using genetics to unlock new research directions

The research used a cutting-edge genetic approach known as Mendelian randomisation to analyse more than 12,000 potentially ‘druggable’ genes – which, along with the proteins they produce, could be targeted by medications. By examining large-scale genetic datasets from hundreds of thousands of individuals, the team identified genes that may play a causal role in vascular dementia.

The study identified four such genes linked to vascular dementia risk:

  • APOE and TOMM40 – well-established genes already known to play roles in brain health and dementia
  • ERAP and SAA1-4 – newer, emerging targets linked to inflammation and immune processes

Importantly, the two strongest signals, APOE and TOMM40, were also associated with brain imaging markers of small vessel disease, a major contributor to both vascular dementia and Alzheimer’s disease. This strengthens the evidence that these genes are involved in underlying disease processes.

A major unmet need

Unlike Alzheimer’s disease – where several treatments exist and many more are in development – vascular dementia research has lagged behind, leaving patients with limited options.

“Managing risk factors like blood pressure and cholesterol helps, but it’s not enough,” Dr Lennon said. “Even under ideal conditions, prevention strategies may only reduce dementia risk by less than half. We urgently need new avenues for research into targeted treatments.”

Cautious optimism for the future

The identification of these genes may help inform future work aimed at:

  • Developing drugs that target pathways relevant to vascular dementia
  • Exploring whether existing medications acting on these genes could be repurposed
  • Improving understanding of how vascular and Alzheimer’s disease processes overlap

However, the researchers emphasise that translating genetic findings into safe and effective treatments is a complex and lengthy process, and many potential drug targets do not ultimately lead to successful therapies.

Professor Perminder Sachdev, Co-Director of CHeBA, said the findings highlight the value of this approach.

“At a time when vascular dementia remains a major unmet medical need, this study highlights the potential of genetics-led research to uncover new treatment pathways and bring hope for future therapies.”

While further work is needed – including laboratory studies, additional genetic analyses and clinical trials – the study provides an important lead for future drug development.

“This is an important first step,” Dr Lennon said. “By identifying potential targets, we can begin to better understand where future research and drug development efforts might be directed.”

About the study

The research was conducted by scientists at UNSW Sydney’s Centre for Healthy Brain Ageing (CHeBA) and funded by the Dementia Australia Research Foundation (DARF) Royce Simmons Project Grant.

 


Contact details:

Dr Matthew Lennon
Centre for Healthy Brain Ageing (CHeBA), UNSW Sydney
Email: [email protected]

Media

More from this category

  • Building Construction, Medical Health Aged Care
  • 20/11/2026
  • 13:49
Asbestos Education Committee & Advocacy Australia

Tradies, Commercial & Non-Residential Property Managers Urged To Respect Asbestos: One Life Lost Every 2 Hours

Key Facts: 1 in 3 Australian homes contain asbestos-containing materials (ACMs), with approximately 6 million tonnes of ageing ACMs remaining in Australia’s built environment.…

  • Contains:
  • Medical Health Aged Care, Political
  • 20/11/2026
  • 11:30
AMA Victoria

Doctors welcome Coalition VicHealth pledge, call for funding certainty

Doctors welcome the Victorian Coalition's commitment to keep VicHealth independent while calling on all parties to protect dedicated, long-term funding for the work that keeps Victorians well. In its response to AMA Victoria's election priorities, the Liberals and Nationals confirmed: “Under the Liberals and Nationals, VicHealth will continue as an independent body. Their work in early intervention and education is vitally important for keeping people out of hospital.” The Victorian Greens and One Nation have also committed to retaining VicHealth's independence.Doctors arecalling onthe Carroll Labor Governmentto reconsider its decision to absorb VicHealth into the Department of Health. That decision followed…

  • Contains:
  • Medical Health Aged Care
  • 20/11/2026
  • 10:36
Dementia Australia

Dementia Australia’s first brand campaign comes to life to reinforce that support is available

Dementia Australia has launched its first brand campaign bringing to life its new brand platform: Support. Change. Prevention, developed with Ogilvy Health Australia.  In 2026, there are an estimated 446,500 Australians living with dementia, and a further 1.7 million people involved in their care. Every day, Dementia Australia supports people impacted by dementia, drives change in how dementia is understood and experienced, and advances prevention through research, education, advocacy and innovation.  Dementia Australia Executive Director – Awareness & Growth Kimberley Roberts said dementia is one of Australia's greatest health challenges and the new campaign “Dementia. Australia. We're changing it” reflects…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.